After the second vaccine dose (three-week-timepoint) S-specific CD4+ T cell responses were detected in all except one CVID patient (18/19, 95%), and the response in CVID patients was comparable to the response seen in HCWs (Figure 2D). This evidence concerns the gene CD4 and common variable immunodeficiency.